WO2001028541A3 - Composition comprising sildenafil and l-arginine - Google Patents

Composition comprising sildenafil and l-arginine Download PDF

Info

Publication number
WO2001028541A3
WO2001028541A3 PCT/IL2000/000622 IL0000622W WO0128541A3 WO 2001028541 A3 WO2001028541 A3 WO 2001028541A3 IL 0000622 W IL0000622 W IL 0000622W WO 0128541 A3 WO0128541 A3 WO 0128541A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sildenafil
arginine
treatment
erectile dysfunction
Prior art date
Application number
PCT/IL2000/000622
Other languages
French (fr)
Other versions
WO2001028541A2 (en
Inventor
Shlomo Laniado
Naftali Stern
Gad Keren
Original Assignee
Shlomo Laniado
Naftali Stern
Gad Keren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shlomo Laniado, Naftali Stern, Gad Keren filed Critical Shlomo Laniado
Priority to AU76826/00A priority Critical patent/AU7682600A/en
Publication of WO2001028541A2 publication Critical patent/WO2001028541A2/en
Publication of WO2001028541A3 publication Critical patent/WO2001028541A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

The present invention relates to a synergistic composition for the treatment of erectile dysfunction comprising suitable amounts of Sildenafil and of L-Arginine or of pharmaceutically acceptable salts thereof. The composition comprises preferably 25 - 100 mg of Sildenafil and 0.5 - 1.5 g of L-Arginine. The composition may comprise suitable excipients and advantageously in oral dosage form. The composition is also for the use of said composition and for the method of treatment for the treatment of erectile dysfunction.
PCT/IL2000/000622 1999-10-19 2000-10-05 Composition comprising sildenafil and l-arginine WO2001028541A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76826/00A AU7682600A (en) 1999-10-19 2000-10-05 Sildenafil preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13246099A IL132460A0 (en) 1999-10-19 1999-10-19 Sildenafil preparation
IL132460 1999-10-19

Publications (2)

Publication Number Publication Date
WO2001028541A2 WO2001028541A2 (en) 2001-04-26
WO2001028541A3 true WO2001028541A3 (en) 2002-03-14

Family

ID=11073348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000622 WO2001028541A2 (en) 1999-10-19 2000-10-05 Composition comprising sildenafil and l-arginine

Country Status (3)

Country Link
AU (1) AU7682600A (en)
IL (1) IL132460A0 (en)
WO (1) WO2001028541A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
TW202332450A (en) * 2022-02-09 2023-08-16 未來新藥股份有限公司 Application of compound combination for preparing medicine of vascular disease treatment capable of accelerating action rate of sildenafil and for long-term administration with low side effects

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
WO2000000212A1 (en) * 1998-06-26 2000-01-06 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
WO2000000212A1 (en) * 1998-06-26 2000-01-06 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALLACE, ARTHUR W. ET AL: "Interaction of L-arginine and phosphodiesterase inhibitors in vasodilatio of the porcine internal mammary artery", ANESTH. ANALG. (BALTIMORE) (2000), 90(4), 840-846, 2000, XP001023695 *

Also Published As

Publication number Publication date
IL132460A0 (en) 2001-03-19
AU7682600A (en) 2001-04-30
WO2001028541A2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
HK1054196A1 (en) Pharmaceutical formulation containing tolterodine and its use
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
WO2001041807A3 (en) Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1426375A3 (en) Analgesic spiroindole derivatives
WO2001041762A3 (en) Valdecoxib compositions
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2002100404A3 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
JP2003503453A5 (en) Synergistic composition comprising gabapentin and pregabalin
WO2001028541A3 (en) Composition comprising sildenafil and l-arginine
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2001019357A3 (en) Combination preparation for the treatment of sexual dysfunction
MY122477A (en) Sertraline oral concentrate
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
RU2002115662A (en) METHOD AND PEPTIDES FOR TREATMENT OF ERECTILE DYSFUNCTION, METHOD AND PHARMACEUTICAL COMPOSITION USING INDICATED PEPTIDES
YU24603A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
HUP0300313A2 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
MXPA04004900A (en) Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease.
WO2004050019A3 (en) Method and compositions for treating anxiety
SE0000782D0 (en) Pharmaceutical formulation and its use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP